CanSino Files for China Approval of COVID-19 Vaccine

Tianjin CanSino Biologics has filed for conditional China approval of its COVID-19 vaccine. In an interim analysis of a global Phase III trial, the vaccine was 65% effective at preventing all symptomatic COVID-19 disease and 90% effective at preventing severe disease. CanSino, which partnered the vaccine with the Beijing Institute of Biotechnology, Academy of Military Medical Sciences , tested it in 40,000 volunteers in five foreign countries. The Ad5-nCoV vaccine is delivered by an adenovirus Type 5 vector. More details.... Stock Symbols: (HK: 6185; SHA: 688185) Share this with colleagues: // //